针对衰弱老年人的个性化照护计划(PROSPER):随机对照试验方案
PROSPER是一项多中心、个体随机对照试验,计划从英格兰北部全科诊所招募1337名65岁及以上、电子衰弱指数评分≥0.21的居家老年人,按2.6:1随机分配至个性化照护计划干预组或常规照护组,评估12个月时健康相关生活质量及成本效果。
要点
- 纳入标准为65岁及以上、电子衰弱指数评分≥0.21、居家、无严重认知障碍且未接受临终照护。
- 干预由Age UK的Personal Independence Co-ordinator在12周内实施,对照为常规照护。
- 主要结局为随机化后12个月时SF-12生理与心理成分评分。
核心结论
- PROSPER研究将评估针对衰弱老年人的个性化照护计划方法的有效性和成本效果,并为其实施过程提供信息。
研究设计与样本
- 多中心、个体随机对照试验,计划从英格兰约克郡-亨伯和中默西地区的全科诊所招募1337名参与者。
- 纳入标准为65岁及以上、电子衰弱指数评分≥0.21、居住在自己家中、无严重认知障碍且未接受临终照护。
- 参与者按2.6:1比例个体随机分配至PROSPER干预组或常规照护组,参与者不设盲,但数据收集和分析设盲。
- 干预由自愿部门组织Age UK内的Personal Independence Co-ordinator工作人员在12周内实施。
- 主要结局为随机化后12个月时使用12条目简短健康问卷的生理和心理成分测量的健康相关生活质量。
关键数值与推荐
- 主要结局为随机化后12个月时SF-12的生理和心理成分评分。
- 次要结局包括随机化后12个月时的日常生活活动、自我管理能力和孤独感、养老院入住、住院以及健康和社会照护资源使用。
- 同时进行平行成本效果和过程评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is common in older age and is characterised by loss of biological reserves across multiple organ systems. These changes associated with frailty mean older people can be vulnerable to sudden, dramatic changes in health because of relatively small problems. Older people with frailty are at increased risk of adverse outcomes including disability, hospitalisation, and care home admission, with associated reduction in quality of life and increased NHS and social care costs. Personalised Care Planning offers an anticipatory, preventative approach to supporting older adults to live independently for longer, but it has not been robustly evaluated in a population of older adults with frailty. METHODS: Following an initial feasibility study, this multi-centre, individually randomised controlled trial aims to establish whether personalised care planning for older people improves health-related quality of life. It will recruit 1337 participants from general practices across Yorkshire and Humber and Mid-Mersey in the North of England. Eligible patients will be aged 65 and over with an electronic frailty index score of 0.21 or above, living in their own homes, without severe cognitive impairment and not in receipt of end-of-life care. Following confirmation of eligibility, informed consent and baseline data collection, participants will be individually randomised to the PeRsOnaliSed care Planning for oldER people with frailty (PROSPER) intervention or usual care in a 2.6:1 allocation ratio. Participants will not be blinded to allocation, but data collection and analysis will be blinded. The intervention will be delivered over 12 weeks by a Personal Independence Co-ordinator worker based within a voluntary sector organisation, Age UK. The primary outcomes are health-related quality of life, measured using both the physical and mental components of the Short-Form 12 Item Health Questionnaire at 12 months after randomisation. Secondary outcomes comprise activities of daily living, self-management capabilities and loneliness, admission to care homes, hospitalisations, and health and social care resource use at 12 months post randomisation. Parallel cost-effectiveness and process evaluations will be conducted alongside the trial. DISCUSSION: The PROSPER study will evaluate the effectiveness and cost-effectiveness of a personalised care planning approach for older people with frailty and inform the process of its implementation. TRIAL REGISTRATION: ISRCTN16123291 . Registered on 28 August 2020.
引用
- Heaven A, Bower P, Day F, et al. PeRsOnaliSed care Planning for oldER people with frailty (PROSPER): protocol for a randomised controlled trial. Trials. 2024. PMID: 38167481. doi:10.1186/s13063-023-07857-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。